Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

292 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: Lessons from the substudy of IFM/DFCI 2009 cohort.
Chalayer E, Talbot A, Frenzel L, Karlin L, Collet P, Guyotat D, Attal M, Leleu X, Tardy B. Chalayer E, et al. Among authors: talbot a. J Thromb Haemost. 2022 Aug;20(8):1859-1867. doi: 10.1111/jth.15758. Epub 2022 May 24. J Thromb Haemost. 2022. PMID: 35557490 Free article. Clinical Trial.
[Multiple myeloma treatment].
Talbot A, Royer B, Roussel M. Talbot A, et al. Rev Prat. 2018 Sep;68(7):787-791. Rev Prat. 2018. PMID: 30869334 French.
Carfilzomib, venetoclax and dexamethasone for relapsed/refractory multiple myeloma.
Boccon-Gibod C, Talbot A, Le Bras F, Frenzel L, Royer B, Harel S, Lombion N, Belhadj K, Cuccuini W, Arnulf B. Boccon-Gibod C, et al. Among authors: talbot a. Br J Haematol. 2020 May;189(3):e73-e76. doi: 10.1111/bjh.16483. Epub 2020 Feb 3. Br J Haematol. 2020. PMID: 32012229 Free article. No abstract available.
Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.
Schavgoulidze A, Talbot A, Perrot A, Cazaubiel T, Leleu X, Manier S, Buisson L, Mahéo S, Do Souto Ferreira L, Pavageau L, Hulin C, Marolleau JP, Voillat L, Belhadj K, Divoux M, Slama B, Brechignac S, Macro M, Stoppa AM, Sanhes L, Orsini-Piocelle F, Fontan J, Chretien ML, Demarquette H, Mohty M, Avet-Loiseau H, Corre J. Schavgoulidze A, et al. Among authors: talbot a. Blood. 2023 Mar 16;141(11):1308-1315. doi: 10.1182/blood.2022017863. Blood. 2023. PMID: 36375118 Free PMC article.
Prognosis of hyperviscosity syndrome in newly diagnosed multiple myeloma in modern-era therapy: A real-life study.
Debureaux PE, Harel S, Parquet N, Lemiale V, Siguret V, Goubeau L, Morin F, Royer B, Cuccuini W, Elessa D, Theves F, Brignier AC, Azoulay E, Arnulf B, Talbot A. Debureaux PE, et al. Among authors: talbot a. Front Immunol. 2022 Dec 8;13:1069360. doi: 10.3389/fimmu.2022.1069360. eCollection 2022. Front Immunol. 2022. PMID: 36569885 Free PMC article.
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study.
Talbot A, Bobin A, Tabone L, Lambert J, Boccaccio C, Deal C, Petillon MO, Allangba O, Agape P, Arnautou P, Belkhir R, Cailleres S, Chaoui D, Chrétien ML, Decaux O, Schulmann S, Frenzel L, Gastaud L, Huart A, Hulin C, Karlin L, Laribi K, Le Calloch R, Lenain P, Macro M, Manier S, Montes L, Moreau S, Moreau P, Morel V, Norwood J, Piocelle FO, Perrot A, Pica GM, Rey P, Schmitt A, Stoppa AM, Tiab M, Touzeau C, Vidal V, Vignon M, Vincent L, Van De Wyngaert Z, Zarnitsky C, Kerbouche N, Paka P, Leleu X, Arnulf B, Avet-Loiseau H, Du Myélome IIF. Talbot A, et al. Haematologica. 2023 Oct 1;108(10):2774-2782. doi: 10.3324/haematol.2022.281772. Haematologica. 2023. PMID: 37078253 Free PMC article.
Inflammation is predictive of outcome in Waldenström macroglobulinemia treated by Bruton tyrosine kinase inhibitors: a multicentric real-life study.
Debureaux PE, Forgeard N, Elessa D, Harel S, Frenzel L, Royer B, Talbot A, Choquet S, Davi F, Nguyen-Khac F, Cuccuini W, Cheminant M, Bravetti C, Lazarian G, Kaltenbach S, Hermine O, Roos-Weil D, Espéli M, Balabanian K, Arnulf B. Debureaux PE, et al. Among authors: talbot a. Haematologica. 2024 Jan 1;109(1):325-330. doi: 10.3324/haematol.2023.283141. Haematologica. 2024. PMID: 37584289 Free PMC article. No abstract available.
Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series.
Forgeard N, Elessa D, Carpinteiro A, Belhadj K, Minnema M, Roussel M, Huart A, Javaugue V, Pascal L, Royer B, Talbot A, Gounot R, Hegenbart U, Schonland S, Karlin L, Harel S, Kastritis E, Bridoux F, Jaccard A, Arnulf B. Forgeard N, et al. Among authors: talbot a. Blood. 2024 Feb 22;143(8):734-737. doi: 10.1182/blood.2023022937. Blood. 2024. PMID: 38096365 No abstract available.
French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry.
Ferment B, Lambert J, Caillot D, Lafon I, Karlin L, Lazareth A, Touzeau C, Leleu X, Moya N, Harel S, Perrot A, Bories P, Vincent L, Lamure S, Mohty M, Malard F, Manier S, Yakoub-Agha I, Schiano De Colella JM, Brisou G, Talbot A, Decaux O, Houot R, Le Gouill S, Bigot N, Facon T, Corre J, Moreau P, Arnulf B; Intergroupe Francophone du Myélome. Ferment B, et al. Among authors: talbot a. Br J Haematol. 2024 Sep;205(3):990-998. doi: 10.1111/bjh.19505. Epub 2024 May 15. Br J Haematol. 2024. PMID: 38747092
Impact of second autologous stem-cell transplantation at relapsed multiple myeloma: A French multicentric real-life study.
André A, Montes L, Roos-Weil D, Frenzel L, Vignon M, Chalopin T, Debureaux PE, Talbot A, Farge A, Jardin F, Belhadj K, Royer B, Marolleau JP, Arnulf B, Morel P, Harel S. André A, et al. Among authors: talbot a. Hemasphere. 2024 Jul 29;8(8):e106. doi: 10.1002/hem3.106. eCollection 2024 Aug. Hemasphere. 2024. PMID: 39081803 Free PMC article.
292 results